Ascletis Pharma Raises $35 Million; Seeks More In-Licensings

Ascletis Pharma, a Hangzhou clinical-stage novel biotech, raised $35 million in a funding led by C-Bridge Capital and joined by Tasly Pharma and Singapore-based Pavilion Capital. The pre-money valuation of Ascletis was $300 million. Ascletis was founded in 2011 with $100 million in startup capital. Ascletis said it would use the proceeds to expand its pipeline, which currently stands at four in-licensed candidates, plus increase its global drug development capability and GMP commercial manufacturing. More details.... Share this with colleagues: // //